11 Pages Posted: 27 Aug 2018 Last revised: 8 Sep 2018
This case introduces salauno, a for-profit company founded by two young entrepreneurs, Javier Okhuysen and Carlos Orellana, who wanted to eliminate needless blindness in Mexico. Untreated cataracts and complications from diabetes were the leading causes of blindness in Mexico as of 2017, and the entrepreneurs aimed to build an inclusive business focusing on low- and middle-income people who were either underserved or completely unserved by the existing Mexican health care market. salauno had experienced high growth since its beginning, but in early 2017, Okhuysen and Orellana faced a crucial test of their company's business model: they wanted to quickly scale the business to serve more patients and take advantage of improvements in cost efficiency, but could the company's financing sustain its ambitious growth plans? Would the existing financial base support salauno's future?
Aug. 6, 2018
In early 2017, salauno faced a crucial test of its business model: Could the company's financing sustain its ambitious growth plans? Founded as a for-profit company in 2011, salauno's mission was to “eliminate needless blindness in Mexico.” The company had grown dramatically and already helped tens of thousands of low-income patients recover or improve their eyesight, thus addressing a major cause of disability in Mexico.
The cofounders, Javier Okhuysen and Carlos Orellana, were extremely proud of salauno's accomplishments and shared ambitious plans for the future. Their goal was to quickly scale the business to serve more patients and take advantage of improvements in cost efficiency, many of which accompanied higher volumes.
To support the growth agenda, salauno had raised MXN80 million in capital in mid-2016. This was on top of prior financings from other private investors since the company's founding. Would the existing financial base support salauno's future?
. . .
Keywords: blindness, underserved markets, Mexico, health care, diversity
Suggested Citation: Suggested Citation
Here is the Coronavirus
related research on SSRN
This is a Darden A Case paper. Darden A Case charges $6.25 .
File name: UVA-F-1830.pdf
If you wish to purchase the right to make copies of this paper for distribution to others, please select the quantity.